![conference banner](/images/conference-banner.jpeg)
[1]
Younis, N.K.; Roumieh, R.; Bassil, E.P.; Ghoubaira, J.A.; Kobeissy, F.; Eid, A.H. Nanoparticles: Attractive tools to treat colorectal cancer. Semin. Cancer Biol., 2022, 86(Pt 2), 1-13.
[http://dx.doi.org/10.1016/j.semcancer.2022.08.006] [PMID: 36028154]
[http://dx.doi.org/10.1016/j.semcancer.2022.08.006] [PMID: 36028154]
[2]
Younis, N.K.; Ghoubaira, J.A.; Bassil, E.P.; Tantawi, H.N.; Eid, A.H. Metal-based nanoparticles: Promising tools for the management of cardiovascular diseases. Nanomedicine, 2021, 36, 102433.
[http://dx.doi.org/10.1016/j.nano.2021.102433] [PMID: 34171467]
[http://dx.doi.org/10.1016/j.nano.2021.102433] [PMID: 34171467]
[3]
Gholami, L.; Ivari, J.R.; Nasab, N.K.; Oskuee, R.K.; Sathyapalan, T.; Sahebkar, A. Recent advances in lung cancer therapy based on nanomaterials: A review. Curr. Med. Chem., 2023, 30(3), 335-355.
[http://dx.doi.org/10.2174/0929867328666210810160901] [PMID: 34375182]
[http://dx.doi.org/10.2174/0929867328666210810160901] [PMID: 34375182]
[4]
Germain, M.; Caputo, F.; Metcalfe, S.; Tosi, G.; Spring, K.; Åslund, A.K.O.; Pottier, A.; Schiffelers, R.; Ceccaldi, A.; Schmid, R. Delivering the power of nanomedicine to patients today. J. Control. Release, 2020, 326, 164-171.
[http://dx.doi.org/10.1016/j.jconrel.2020.07.007] [PMID: 32681950]
[http://dx.doi.org/10.1016/j.jconrel.2020.07.007] [PMID: 32681950]
[5]
Akter, Z.; Khan, F.Z.; Khan, M.A. Gold nanoparticles in triple-negative breast cancer therapeutics. Curr. Med. Chem., 2023, 30(3), 316-334.
[http://dx.doi.org/10.2174/0929867328666210902141257] [PMID: 34477507]
[http://dx.doi.org/10.2174/0929867328666210902141257] [PMID: 34477507]
[6]
Kemp, J.A.; Kwon, Y.J. Cancer nanotechnology: Current status and perspectives. Nano Converg., 2021, 8(1), 34.
[http://dx.doi.org/10.1186/s40580-021-00282-7] [PMID: 34727233]
[http://dx.doi.org/10.1186/s40580-021-00282-7] [PMID: 34727233]
[7]
Manohar, S.; Leung, N. Cisplatin nephrotoxicity: A review of the literature. J. Nephrol., 2018, 31(1), 15-25.
[http://dx.doi.org/10.1007/s40620-017-0392-z] [PMID: 28382507]
[http://dx.doi.org/10.1007/s40620-017-0392-z] [PMID: 28382507]
[8]
Staff, N.P.; Fehrenbacher, J.C.; Caillaud, M.; Damaj, M.I.; Segal, R.A.; Rieger, S. Pathogenesis of paclitaxel-induced peripheral neuropathy: A current review of in vitro and in vivo findings using rodent and human model systems. Exp. Neurol., 2020, 324, 113121.
[http://dx.doi.org/10.1016/j.expneurol.2019.113121] [PMID: 31758983]
[http://dx.doi.org/10.1016/j.expneurol.2019.113121] [PMID: 31758983]
[9]
Mirhadi, E.; Majeed, M.; Kesharwani, P.; Sahebkar, A. Reactive oxygen species-responsive drug delivery systems: A new approach in nanomedicine. Curr. Med. Chem., 2022, 29(25), 4320-4323.
[http://dx.doi.org/10.2174/0929867329666220127110654] [PMID: 35086442]
[http://dx.doi.org/10.2174/0929867329666220127110654] [PMID: 35086442]
[10]
Khan, F.; Akhtar, S.; Kamal, M.A. Nanoinformatics and personalized medicine: An advanced cumulative approach for cancer management. Curr. Med. Chem., 2022, 29.
[http://dx.doi.org/10.2174/0929867329666220610090405] [PMID: 35692148]
[http://dx.doi.org/10.2174/0929867329666220610090405] [PMID: 35692148]
[11]
Wei, G.; Wang, Y.; Yang, G.; Wang, Y.; Ju, R. Recent progress in nanomedicine for enhanced cancer chemotherapy. Theranostics, 2021, 11(13), 6370-6392.
[http://dx.doi.org/10.7150/thno.57828] [PMID: 33995663]
[http://dx.doi.org/10.7150/thno.57828] [PMID: 33995663]
[12]
Hamze, K.; Abdallah, R.H.; Younis, N.K.; Fardoun, M.; Darwiche, N.; Kobeissy, F.; Iratni, R.; Bouhadir, K.; Eid, A.H. 2-Nucleobase-substituted 4,6-diaminotriazine analogs: Synthesis and anti-cancer activity in 5-fluorouracil-sensitive and resistant colorectal cancer cells. Curr. Med. Chem., 2022.
[PMID: 36111761]
[PMID: 36111761]
Article Metrics
![Wayfinder Image](/images/wayfinder.jpg)